Back to Sites Molepolole CRS Site Number 12702 Address Molepolole Prevention/Treatment Trials CRS Scottish Livingstone Hospital Gaborone-Molepolole Road Molepolole, Botswana IMPAACT Members at this Site Chenesani Bohule Clinical Research Assistant Ayotunde Omoz-Oarhe Co-Investigator Mpho Raesi CRS Coordinator Akeem Salawu CRS Coordinator Gaerolwe Masheto CRS Leader Ayotunde Omoz-Oarhe CRS Leader Ponego Ponatshego CRS Leader Gaerolwe Masheto CTU Coordinator Shahin Lockman CTU Principal Investigator Joseph Makhema CTU Principal Investigator Sue Welsch DAIDS PO Farida Monggae Data Manager Masego Rankowa Data Manager Rasak Abdullahi Investigator Unoda Chakalisa Investigator Kenneth Maswabi Investigator Sikhulile Moyo Laboratory Manager/Supervisor Lesedi Tirelo Laboratory QA/QC Coordinator Motswedi Anderson Laboratory Technician/Technologist Rufaro Mangwarara Pharmacist Tshepho Frank Pharmacy Supervisor Urunduruka Munamava QA/QC Coordinator Tumalano Sekoto Regulatory Coordinator Tebogo Kakhu Staff Tebogo Mokotedi Staff Kelechi Nnajide Staff Anthony Ogwu Staff Studies at this Site IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status In Development IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure and Immunotherapy Study Status Enrolling IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Therapeutics Study Status Closed to Accrual IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling IMPAACT 2039: EXCEED DAIDS Number 38,988 Research Area Cure and Immunotherapy Study Status In Development Pagination Previous page Prev Page 1 Current page 2
IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status In Development
IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure and Immunotherapy Study Status Enrolling
IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling
IMPAACT 2039: EXCEED DAIDS Number 38,988 Research Area Cure and Immunotherapy Study Status In Development